Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veracyte reports record Q4 revenue and strategic growth initiatives

Veracyte's Q4 performance reflects strong financials and product advancements, positioning the company for continued growth.
While facing challenges in cost management and operational transitions, Veracyte remains proactive in addressing market demands.
Opportunities for revenue growth and market expansion through new product developments and reimbursement progress are key focus areas.
Overall, Veracyte's strategic initiatives and market positioning suggest a promising outlook for future success.

Veracyte reports robust Q1 earnings, eyes global expansion opportunities

Veracyte's strong Q1 performance was driven by Afirma and Decipher tests, despite challenges in the biopharma business.
The company's focus on global expansion, product enhancement, and evidence generation positions it well for future growth.
Challenges in margins and customer spending require strategic adjustments, but Veracyte remains optimistic about its investment levels.
ESG efforts and commitment to patient outcomes underscore Veracyte's dedication to transforming healthcare and stakeholder value.

Veracyte reports strong Q2 earnings, raises 2023 revenue outlook

Veracyte's Q2 performance reflects robust revenue growth, operational efficiency, and increased market confidence.
While facing challenges in the biopharma segment and manufacturing transitions, the company is well-positioned to capitalize on market opportunities.
With raised revenue projections, strong product performance, and strategic focus areas, Veracyte is poised for continued growth and market expansion.

Veracyte (VCYT) reports robust Q3 performance and eyes market expansion

Veracyte (VCYT) delivered strong financial results in Q3 2023, driven by core testing business growth and strategic partnerships.
Despite supply chain challenges, the company remains focused on market expansion, operational optimization, and cash flow generation.
With a positive outlook for 2024 and a focus on evidence generation and market penetration, Veracyte is poised for continued growth and transformation in cancer care.

Veracyte reports record 2023 revenue, eyes market expansion in 2024

Veracyte's strong 2023 performance sets the stage for continued growth in 2024.
Balancing short-term challenges with long-term opportunities for market expansion.
Strategic acquisitions and product developments position Veracyte well in evolving markets.
Maintaining financial guidance and operational focus key to sustained success.

Veracyte's Q1 2024 earnings call showcased strong revenue growth driven by Decipher Prostate and Afirma.
The company raised total revenue guidance for 2024 and highlighted interest from biopharma in data projects.
While facing challenges like FDA LDT regulation, Veracyte remains focused on existing growth drivers and global expansion.
Excitement surrounds the company's growth trajectory and opportunities in Decipher, MRD testing, and new cancer challenges.

Veracyte reports stellar Q2 results, eyes revenue growth opportunities

Veracyte's Q2 2024 performance reflects robust revenue growth, driven by strong testing revenue and strategic initiatives focused on market expansion and innovation.
Despite facing seasonal revenue fluctuations, the company remains optimistic about achieving its raised revenue guidance for 2024, underpinned by the growth in testing business.
The emphasis on profitability, cash generation, and revenue growth through Decipher and Afirma positions Veracyte well for sustained financial success and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company's Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1. Together, these abstracts offer novel insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data from t.

Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company's in vitro diagnostics (IVD) Business Unit, based in Marseille, France. She will lead the global expansion of Veracyte's tests and will also serve as site lead for the company's Marseille operations. Dr. Taine is a highly credentialed commercial operations leader with 30 years of experience in the medical device and pharmaceut.

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company's Tests

SOUTH SAN FRANCISCO, Calif. & PARIS--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies. The multi-year partnership will leverage Gustave Rouss.

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

Veracyte's revenue sharply rose in the second quarter. The company is moving toward profitability.

Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, at 4:15 p.m. Eastern Time. A live audio webcast of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay.

Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Published Findings Suggest Potential of Veracyte's Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer.

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that its South San Francisco and San Diego offices have been named top workplaces. Veracyte's South San Francisco location has been awarded a Top Bay Area Workplaces 2023 honor by the San Francisco Chronicle, in partnership with Energage, LLC. This is Veracyte's tenth consecutive year receiving this honor. Additionally, Veracyte's San Diego office has received its inaugural Best Places to Work in San Diego awa.

Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego

Veracyte (VCYT) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.13 per share a year ago.

Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023. “We delivered outstanding second quarter results, with revenue and test volume that exceeded our expectations. We also generated a record $17 million in cash from operations this quarter, driven by our exceptional top-line performance and strong cash collections,” said Marc Stapley, Veracyte's chief executive officer. “The compelling clinical.

Veracyte Announces Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--JNCI Cancer Spectrum Publication Demonstrates Real-World Utility of Veracyte's Decipher Prostate Genomic Classifier in Prostate Cancer Treatment.

Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte's Decipher Prostate Genomic Classifier in Prostate Cancer Treatment

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday, August 8, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link:.

Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023

AbCellera Biologics

Recursion Pharmaceuticals

AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer.

New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023.

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte's Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer.

New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte's Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C. Findings from two posters suggest that the Envisia Genomic Classifier helps improve diagnosis and.

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte's Genomic Tests in Interstitial Lung Disease and Lung Cancer

Growing demand for Veracyte's diagnostic tests helped its top line surge in Q1. The company could turn a profit as early as the second half of this decade.

Here's Why This Little-Known Growth Stock Is a Buy

With its range of products, Veracyte displays a robust and diverse portfolio, targeting multiple areas in oncology. Veracyte's recent data underscores the company's innovative edge in the field of genomic diagnostics, specifically with the Decipher Prostate Genomic Classifier.

Veracyte: Investing In The Future Of Genomic Diagnostics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing – specifically, the Prosigna te.

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte, Inc. (NASDAQ:VCYT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Mason Carrico - Stephens, Inc. Matt Sykes - Goldman Sachs Andrew Brackmann - William Blair Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2023 Financial Results Webcast.

Veracyte, Inc. (VCYT) Q1 2023 Earnings Call Transcript

Veracyte (VCYT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.20 per share a year ago.

Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2023. “We had an excellent first quarter, as many areas of our business greatly exceeded our expectations. Not only did we deliver strong Afirma and Decipher growth, we also demonstrated continued financial discipline and outstanding execution, which resulted in a meaningfully higher cash balance than we had projected,” said Marc Stapley, Veracyte's.

Veracyte Announces First Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report. The 2023 ESG Report sets the foundation for Veracyte's ESG performance and outlines the company's ambitions to build upon its progress in the years ahead. “As our company has grown, we have embraced our responsibility to advance our ESG efforts,” said Marc Stapley, Veracyte's chief executive officer. “Our inaugural ESG repo.

Veracyte Announces Release of Inaugural ESG Report

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Published Data Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier To Help Guide Therapy in Intermediate-Risk Prostate Cancer.

Data Published in "The Red Journal” Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company's genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24 in Washington, D.C. “We look forward to these new data being shared at ATS 2023, which explore the impact of our Envisia Gen.

Three Abstracts Focusing on the Clinical Utility of Veracyte's Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

News for Veracyte Stock (VCYT)